Trends in antihypertensive drug utilization in British Columbia, 2004–2019: a descriptive study
暂无分享,去创建一个
[1] K. Kario,et al. Seasonal variation in blood pressure: current evidence and recommendations for hypertension management , 2021, Hypertension Research.
[2] A. Pottegård,et al. Use of hydrochlorothiazide in Denmark following publication of skin cancer risk findings , 2021, Pharmacoepidemiology and drug safety.
[3] A. S. Kim,et al. Etiology and management of hypertension in patients with cancer , 2021, Cardio-Oncology.
[4] B. Manns,et al. Antihypertensive Prescribing for Uncomplicated, Incident Hypertension: Opportunities for Cost Savings , 2021, CJC open.
[5] M. Johansen,et al. The Ecology of Antihypertensives in the United States, 1997–2017 , 2020, Journal of General Internal Medicine.
[6] Lawrence A Leiter,et al. Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. , 2020, The Canadian journal of cardiology.
[7] M. Johansen,et al. The Ecology of Antihypertensives in the United States, 1997-2017 , 2020, medRxiv.
[8] Jiang He,et al. The global epidemiology of hypertension , 2020, Nature Reviews Nephrology.
[9] George Hripcsak,et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis , 2019, The Lancet.
[10] L. Lix,et al. Trends in chronic disease incidence rates from the Canadian Chronic Disease Surveillance System. , 2019, Health promotion and chronic disease prevention in Canada : research, policy and practice.
[11] F. McAlister,et al. The History of Hypertension Guidelines in Canada. , 2019, The Canadian journal of cardiology.
[12] G. Mancia,et al. Two-Drug Combinations as First-Step Antihypertensive Treatment. , 2019, Circulation research.
[13] H. Quan,et al. Prevalence of Hypertension, Treatment, and Blood Pressure Targets in Canada Associated With the 2017 American College of Cardiology and American Heart Association Blood Pressure Guidelines , 2019, JAMA network open.
[14] G. Lip,et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.
[15] Jackson T. Wright,et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2018, Journal of the American Society of Hypertension : JASH.
[16] A. Pottegård,et al. Association of Hydrochlorothiazide Use and Risk of Malignant Melanoma , 2018, JAMA internal medicine.
[17] L. Tomlinson,et al. Seventeen-Year Nationwide Trends in Antihypertensive Drug Use in Denmark. , 2017, The American journal of cardiology.
[18] A. Pottegård,et al. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case‐control study from Denmark , 2017, Journal of the American Academy of Dermatology.
[19] G. Nijpels,et al. Factors associated with antihypertensive medication non-adherence: a systematic review , 2017, Journal of Human Hypertension.
[20] B. Dobbs,et al. Secondary Hypertension: Discovering the Underlying Cause. , 2017, American family physician.
[21] J. Hallas,et al. Hydrochlorothiazide use is strongly associated with risk of lip cancer , 2017, Journal of internal medicine.
[22] Jason P Fine,et al. Practical recommendations for reporting Fine‐Gray model analyses for competing risk data , 2017, Statistics in medicine.
[23] M. Abrahamowicz,et al. Comparative effectiveness of antihypertensive drugs in nondiabetic patients with hypertension: A population‐based study , 2017, Journal of clinical hypertension.
[24] Lawrence A Leiter,et al. Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. , 2017, The Canadian journal of cardiology.
[25] P. McFarlane,et al. Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. , 2016, The Canadian journal of cardiology.
[26] F. McAlister,et al. Epidemiology of Hypertension in Canada: An Update. , 2016, The Canadian journal of cardiology.
[27] S. Anderson,et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis , 2016, The Lancet.
[28] F. Messerli,et al. Efficacy of Low-Dose Chlorthalidone and Hydrochlorothiazide as Assessed by 24-h Ambulatory Blood Pressure Monitoring. , 2016, Journal of the American College of Cardiology.
[29] M. Woodward,et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis , 2016, The Lancet.
[30] L. Smeeth,et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement , 2015, PLoS medicine.
[31] M. Tonelli,et al. Healthcare Costs Attributable to Hypertension: Canadian Population-Based Cohort Study. , 2015, Hypertension.
[32] J. Kostis,et al. Head-to-Head Comparisons of Hydrochlorothiazide With Indapamide and Chlorthalidone: Antihypertensive and Metabolic Effects , 2015, Hypertension.
[33] L. Brewster,et al. Effects of Thiazide-Type and Thiazide-Like Diuretics on Cardiovascular Events and Mortality: Systematic Review and Meta-Analysis , 2015, Hypertension.
[34] J. Václavík,et al. Reasons for Switching Antihypertensive Medication in General Practice , 2014, Medicine.
[35] G. Mancia,et al. Individualization of Antihypertensive Drug Treatment , 2013, Diabetes Care.
[36] H. Parise,et al. Initial Combination Therapy Reduces the Risk of Cardiovascular Events in Hypertensive Patients: A Matched Cohort Study , 2013, Hypertension.
[37] F. McAlister,et al. Canadian provincial trends in antihypertensive drug prescriptions between 1996 and 2006. , 2011, The Canadian journal of cardiology.
[38] F. McAlister,et al. Antihypertensive drug persistence and compliance among newly treated elderly hypertensives in ontario. , 2010, The American journal of medicine.
[39] D. Ellison,et al. Thiazide Effects and Adverse Effects: Insights From Molecular Genetics , 2009, Hypertension.
[40] G. Bakris,et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. , 2008, The New England journal of medicine.
[41] A. Rodgers,et al. Global burden of blood-pressure-related disease, 2001 , 2008, The Lancet.
[42] Yu-Kang Tu,et al. Simpson's Paradox, Lord's Paradox, and Suppression Effects are the same phenomenon – the reversal paradox , 2008, Emerging themes in epidemiology.
[43] G. Skrepnek,et al. Persistence, Adherence, and Risk of Discontinuation Associated with Commonly Prescribed Antihypertensive Drug Monotherapies , 2007, The Journal of the American Board of Family Medicine.
[44] R. Stafford,et al. Changes in Antihypertensive Prescribing During US Outpatient Visits for Uncomplicated Hypertension Between 1993 and 2004 , 2006, Hypertension.
[45] S. Morgan,et al. Toward a standard definition and measurement of persistence with drug therapy: Examples from research on statin and antihypertensive utilization. , 2006, Clinical therapeutics.
[46] Thomas A Burke,et al. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice , 2006, Journal of hypertension.
[47] M. Brisson,et al. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study , 2005, Journal of Human Hypertension.
[48] A. Ciampi,et al. Determinants of discontinuation of new courses of antihypertensive medications. , 2002, Journal of clinical epidemiology.
[49] Thomas Kahan,et al. [2018 ESC/ESH Guidelines for the management of arterial hypertension]. , 2019, Kardiologia polska.
[50] Daniel W. Jones,et al. Potential U.S. Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline. , 2018, Journal of the American College of Cardiology.
[51] V. Musini,et al. First-line drugs for hypertension. , 2018, The Cochrane database of systematic reviews.
[52] C. Escobar Cervantes,et al. [A randomized trial of intensive versus standard blood pressure control]. , 2016, Semergen.
[53] H. M. A. Abraham,et al. The Comparative Efficacy and Safety of the Angiotensin Receptor Blockers in the Management of Hypertension and Other Cardiovascular Diseases , 2014, Drug Safety.
[54] D. Wald,et al. Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials , 2010 .